ClinicalTrials.Veeva

Menu
S

Sanatorio Allende | Departamento de Investigación Clínica

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Atezolizumab
Carboplatin
Paclitaxel
Milvexian
Cytarabine
Pembrolizumab
Venetoclax
Tiragolumab
Fulvestrant
RO7434656

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 32 total trials

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Enrolling
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Drug: Fulvestrant
Drug: Dexamethasone Mouth Rinse

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantama...

Active, not recruiting
Advanced or Metastatic Non-small Cell Lung Cancer
Drug: Lazertinib
Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of...

Active, not recruiting
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Drug: Cytarabine
Drug: Dexamethasone

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administere...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Drug: Atezolizumab
Drug: Placebo

The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS)...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, b...

Enrolling
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)
Drug: Giredestrant

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with International Society of N...

Active, not recruiting
Lupus Nephritis
Drug: Obinutuzumab
Drug: MMF

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RO7434656, a novel Antisense Oligonucleotide (ASO) therapy in...

Enrolling
Primary IgA Nephropathy
Drug: RO7434656
Drug: Placebo

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of GDC-1971 when administered in combination with atezolizum...

Enrolling
Advanced Solid Tumors
Metastatic Solid Tumors
Drug: Omeprazole
Drug: GDC-1971

The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: M7824

The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative t...

Enrolling
Non-small Cell Lung Cancer
Drug: Domvanalimab
Drug: Nab-paclitaxel

Trial sponsors

Roche logo
Janssen (J&J Innovative Medicine) logo
Merck KGaA (EMD Serono) logo
AbbVie logo
Genentech logo
Gilead Sciences logo
Pfizer logo
Boehringer Ingelheim logo
Daiichi Sankyo logo
Fresenius Kabi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems